PNC Financial Services Group’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-13,000
| Closed | -$64K | – | 4736 |
|
|
2021
Q3 | $64K | Buy |
13,000
+3,000
| +30% | +$14.6K | ﹤0.01% | 2925 |
|
|
2021
Q2 | $53K | Hold |
10,000
| – | – | ﹤0.01% | 3042 |
|
|
2021
Q1 | $48K | Buy |
10,000
+3,000
| +43% | +$15.7K | ﹤0.01% | 3012 |
|
|
2020
Q4 | $30K | Sell |
7,000
-8,000
| -53% | -$34.2K | ﹤0.01% | 3184 |
|
|
2020
Q3 | $62K | Hold |
15,000
| – | – | ﹤0.01% | 2606 |
|
|
2020
Q2 | $38K | Buy |
15,000
+3,000
| +25% | +$8.82K | ﹤0.01% | 2906 |
|
|
2020
Q1 | $35K | Hold |
12,000
| – | – | ﹤0.01% | 2828 |
|
|
2019
Q4 | $45K | Hold |
12,000
| – | – | ﹤0.01% | 2953 |
|
|
2019
Q3 | $61K | Buy |
12,000
+2,000
| +20% | +$12.3K | ﹤0.01% | 2791 |
|
|
2019
Q2 | $62K | Buy |
10,000
+4,000
| +67% | +$23K | ﹤0.01% | 2828 |
|
|
2019
Q1 | $43K | Buy |
+6,000
| New | +$54K | ﹤0.01% | 3033 |
|
|
2018
Q4 | – | Sell |
-3,000
| Closed | -$60K | – | 4242 |
|
|
2018
Q3 | $60K | Hold |
3,000
| – | – | ﹤0.01% | 2896 |
|
|
2018
Q2 | $77K | Hold |
3,000
| – | – | ﹤0.01% | 2723 |
|
|
2018
Q1 | $72K | Hold |
3,000
| – | – | ﹤0.01% | 2753 |
|
|
2017
Q4 | $102K | Hold |
3,000
| – | – | ﹤0.01% | 2554 |
|
|
2017
Q3 | $64K | Sell |
3,000
-15
| -0.5% | -$275 | ﹤0.01% | 2796 |
|
|
2017
Q2 | $53K | Buy |
3,015
+15
| +0.5% | +$248 | ﹤0.01% | 2867 |
|
|
2017
Q1 | $53K | Hold |
3,000
| – | – | ﹤0.01% | 2856 |
|
|
2016
Q4 | $51K | Hold |
3,000
| – | – | ﹤0.01% | 2831 |
|
|
2016
Q3 | $49K | Sell |
3,000
-62
| -2% | -$942 | ﹤0.01% | 2828 |
|
|
2016
Q2 | $46K | Sell |
3,062
-2
| -0.1% | -$33 | ﹤0.01% | 2878 |
|
|
2016
Q1 | $44K | Buy |
3,064
+2
| +0.1% | +$34 | ﹤0.01% | 2892 |
|
|
2015
Q4 | $87K | Buy |
3,062
+3,000
| +4,839% | +$50.5K | ﹤0.01% | 2536 |
|
|
2015
Q3 | $1K | Buy |
62
+2
| +3% | +$46 | ﹤0.01% | 4529 |
|
|
2015
Q2 | $2K | Buy |
60
+26
| +76% | +$506 | ﹤0.01% | 4458 |
|
|
2015
Q1 | $1K | Sell |
34
-66
| -66% | -$1.13K | ﹤0.01% | 4565 |
|
|
2014
Q4 | $2K | Buy |
+100
| New | +$1.52K | ﹤0.01% | 3854 |
|
PNC Financial Services Group's ADMS Position: Q4 2021 in Review
PNC Financial Services Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 13,000 shares — an estimated $64K sold.
PNC Financial Services Group first reported a position in ADMS in Q4 2014 and held it in 27 quarters. The position peaked at $102K in Q4 2017. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- PNC Financial Services Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- PNC Financial Services Group sold 13,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $64K.
- PNC Financial Services Group first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 27 quarters.
- PNC Financial Services Group's Adamas Pharmaceuticals position peaked at $102K in Q4 2017.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on PNC Financial Services Group's 13F filing for Q4 2021, filed 11 Feb 2022.